BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) reported today updated results from a Phase I clinical trial of sapacitabine (CYC682), a novel orally available nucleoside analog, at the 49th Annual Meeting of the American Society of Hematology, December 8 - 11, 2007 in Atlanta, Georgia. Data from this study demonstrated that sapacitabine had a favorable safety profile and promising anti-leukemic activity in patients with relapsed and refractory acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) when administered by two different dosing schedules.
